<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon syndrome</z:e> (SS) is characterized by <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e>, recurrent <z:hpo ids='HP_0002140'>ischemic strokes</z:hpo>, and often progressive vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment options for SS center on either anticoagulation or immunosuppression to prevent <z:hpo ids='HP_0001297'>strokes</z:hpo> and to dissipate the skin findings, with these modalities based historically on the presence or absence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:chebi fb="21" ids="53713">APA</z:chebi>) respectively </plain></SENT>
<SENT sid="2" pm="."><plain>However, few effective treatments have been reported to reverse the <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in SS </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of a woman with seronegative SS (absence of <z:chebi fb="21" ids="53713">APA</z:chebi>) with <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> who demonstrated objective and subjective improvements in her memory and emotional functioning after treatment with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
</text></document>